While it did not robustly differentiate disease severity in our study, further investigation in larger, longitudinal, and multicenter cohorts, including assessments of type 2 biomarkers (FeNO, total IgE) and measures of airway remodeling, is warranted to clarify periostin’s utility in precision asthma management. The gene discussed is POSTN; the disease is asthma.